Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Klebsiella pneumoniae capsular polysaccharide is a structurally diverse extracellular carbohydrate essential for virulence due to its roles in immune evasion and environmental adaptation. Its biosynthesis involves complex genetic loci encoding multiple enzymes responsible for assembly/export. Because it is both highly immunogenic yet variable between strains—and crucial to pathogenesis—it remains both a challenge and opportunity as a therapeutic/vaccine target against multidrug-resistant K. pneumoniae.
Glycoconjugate vaccines: Induce serotype-specific antibody production to promote opsonization and phagocytosis. Phage-derived depolymerases: Degrade the capsule, rendering bacteria susceptible to immune clearance and antibiotics.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Klebsiella pneumoniae Capsular Polysaccharide (CPS).